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James W DoddAbstract
Almost 40 million people currently live with dementia but this is estimated to double over the next 20 years; despite
this, research identifying modifiable risk factors is scarce. There is increasing evidence that cognitive impairment is more
frequent in those with chronic lung disease than those without. Chronic obstructive pulmonary disease affects 210
million people, with cognitive impairment present in 60% of certain populations. Co-morbid cognitive dysfunction also
appears to impact on important outcomes such as quality of life, hospitalisation and survival. This review summarises
the evidence of an association between cognition, impaired lung function and obstructive lung disease. It goes on to
examine the contribution of neuro-imaging to our understanding of the underlying pathophysiology. While the
mechanisms of brain pathology and cognitive impairment are likely to be complex and multi-factorial, there is
evidence to suggest a key role for occult cerebrovascular damage independent of traditional vascular risk factors,
including smoking.Introduction
The World Health Organization reports that 35.6 million
people currently live with dementia but this is estimated
to double over the next 20 years; despite this, research
identifying modifiable risk factors is scarce. Mild cognitive
impairment (MCI) is associated with a 5 to 10% annual
conversion rate to dementia [1,2]. However, MCI is con-
sidered a potentially reversible state and not all of those
with MCI go on to develop dementia. Therefore, clarifying
which features predict progression to dementia and
identifying modifiable targets is currently of great inter-
est. The diagnosis of MCI generally requires the exclu-
sion of co-morbid illness but there have been concerns
about the generalisability of this approach given that
50% of those with MCI are thought to have a medical
co-morbidity [3]. Chronic lung disease is one such medical
co-morbidity with increasing evidence of an association
with cognitive dysfunction and brain pathology.Lung function and cognitive impairment
Individuals with chronic lung disease are thought to be
at an increased risk of cognitive decline. This may be as
a result of risk factors which occur more frequently inCorrespondence: james.dodd@bris.ac.uk
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unless otherwise stated.those with lung disease (that are already known to nega-
tively impact on cognition, such as smoking and hyperten-
sion) and/or as a direct result of respiratory limitations
(such as hypoxaemia). Figure 1 summarises some of the
overlapping risk factors for cognitive impairment in both
general and chronic lung disease populations. However,
importantly it seems that there is an association between
cognitive impairment and lung disease independent of
these factors [4].
Lung function is most often measured by spirometry,
giving forced expiratory volume in 1 second (FEV1) and
forced vital capacity, standardised for age and gender.
The association between lung function and cognition
has been tested in a number of large healthy population
studies, particularly in elderly groups [4]. The majority of
studies support at least some independent association be-
tween lung function and cognitive performance (Table 1).
The most comprehensive study comes from a longitu-
dinal analysis of over 10,000 healthy men and women with
repeated cognitive assessments between 1990 and 2006.
This showed that impaired lung function was independ-
ently associated with worse cognitive function at baseline
and higher subsequent risk of dementia hospitalization.
However, no association was found between lung function
and cognitive decline over time [5]. Other studies havean Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Risk factors for cognitive impairment in both general
and chronic lung disease populations. This material has not been
reviewed by the European Respiratory Society prior to release;
therefore, the European Respiratory Society may not be responsible
for any errors, omissions or inaccuracies, or for any consequences
arising therefrom, in the content. Reproduced with permission of
the European Respiratory Society [4].




N = 10,975 men + women aged
47–70 years. Atherosclerosis Risk
in Communities (ARIC) Study
Vietnam veteran study N = 4,256 men aged 20 years
Prospective observational
study





N = 3,635; N = 1,281 subset 2/3
serial FEV1 over 7.8 years
Longitudinal population
Swedish Twin Study
N = 832 (50–85 year olds);
19 year follow-up
Longitudinal 23 year follow-up N = 3,036 Japanese American
males in Hawaii
Healthy Longitudinal All ages N = 2,551
MRC National Survey of
Health and Development
N = 1,778 men and women
FEV1, forced expiratory volume in 1 second; MCI, mild cognitive impairment; MRC,
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have been found they are not universal [6]. For example,
mid-life lung function predicts mid-life psychomotor
ability, memory, processing speed and executive func-
tion, but only psychomotor ability declined significantly
over time [7,8]. Age is understood to be the most sig-
nificant predictor of cognition and FEV1 also declines
with age. However, FEV1 has been shown to be signifi-
cantly and independently associated with cognitive
function in all ages groups, though correlations can be
weak [9,10].
Overall it appears that lung function is independently
associated with measures of cognition and rate of
cognitive decline. A lack of standardised neuropsycho-
logical assessments and variability in adjustment for
confounders between studies currently limit clinical
interpretation.
Obstructive lung diseases
Chronic obstructive pulmonary disease
One of the most common causes of impaired lung func-
tion is chronic obstructive pulmonary disease (COPD),
a preventable and treatable disease characterised byComment Reference
Reduced lung function was associated with worse
performance in cognitive assessments and with an
increased risk of dementia hospitalization. No
association was found between lung function and
cognitive decline over time
[5]
Poor cognitive ability in mid-life associated with
reduced lung function in mid-life. Effects size small.
Similar effects in non-smokers
[9]
Baseline FEV1 associated with visuo-spatial and
global ability. Higher FEV1 associated with slower
decline only in attention. Rate of decline in FEV1
not associated with cognition. Overall limited
evidence of a relationship between FEV1 and
cognitive decline
[6]
Low mid-life FEV1/height predicted poor memory,
processing speed, executive function MCI and
dementia 23 years later. Decline in lung function
over 7.8 years in mid-life was not associated with
MCI or dementia
[8]
Changes in lung function led to subsequent
changes in psychomotor speed and spatial abilities.
No evidence that declines in cognitive function lead
to subsequent decline in lung function
[83]
Baseline FEV1 predict cognitive function (Cognitive
Abilities Screening Instrument - CASI)
[84]
FEV1 associated with cognitive function in all age
groups, although significant associations were
weak
[10]
Mid-life FEV1 associated with mid-life psychomotor
speed and decline over 10 years
[7]
Medical Research Council.
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and associated with an enhanced chronic inflamma-
tory response in the airways and the lung to noxious
particles or gases, most commonly tobacco smoke
[11]. Unlike other common chronic diseases, the glo-
bal prevalence of COPD has increased in recent
years. In the UK, 10% of adults have an abnormally
low FEV1 and 210 million people are diagnosed with
COPD around the world. COPD is projected to be-
come the third leading cause of death by 2030 [12],
with smoking cessation the most effective inter-
vention to reduce the risk of developing COPD and
prevent disease progression [13,14]. Associations be-
tween COPD and cognitive function are explored in
detail below.
Asthma
It is estimated that 300 million people suffer with
asthma globally, with prevalence rates of around
15.3% in England [15]. Asthma is defined clinically by
the presence of symptoms (more than one of wheeze,
breathlessness, chest tightness, cough) and of variable
airflow obstruction. Unlike COPD, asthma predomin-
antly affects children and young adults; it is most
commonly associated with atopy and inflammation
(allergy, eczema and hayfever) rather than smoking
exposure.
Several studies suggest an association between neu-
rocognitive dysfunction and asthma, citing mecha-
nisms such as sleep disturbance, medication effects
and systemic inflammation [16-26]. Mid-life asthma
in particular has been associated with incidence of
cognitive impairment and dementia (hazard ratios of
1.88 and 1.27, respectively), with risks increased fur-
ther with exacerbation and hospitalisations [23-26]. In
a study of 46 atopic patients with asthma, cognitive
function was measured at baseline and 6 weeks after
inhaled bronchodilators and steroids. This showed an
improvement in cognition which appeared to relate
to an improvement in variability of lung function, al-
though it is not clear that practice and regression to
the mean effects were fully accounted for [24]. A
similar number of studies suggest no significant asso-
ciation between asthma and cognitive impairment
[27-31]. The Childhood Asthma Management Pro-
gram involved 1,041 children aged 5 to 12 years with
asthma who were assessed prior to randomisation to
receive anti-inflammatory medications. Neurocognitive
performance was found to be normal and not associ-
ated with measures of asthma severity [27]. Flannery
and colleagues [30] examined cognitive function in
11,578 children and found little support for a link be-
tween asthma and neurodevelopment problems. There
were mixed results from an analysis of the SwedishTwin Registry, which showed a very modest longitu-
dinal association between atopy and dementia (hazard
ratio 1.16) in a large study of 22,188 people [20].
In many of these studies, sample sizes and multiple
confounders in case definition limit definitive interpretation,
leading some authors to conclude that socio-economic
factors are mainly responsible for the variation in
school performance and neurocognitive ability in
asthma [32].
Chronic obstructive pulmonary disease - a multi system
disease
It is widely accepted that patients with COPD suffer
with systemic manifestations beyond the lung and that
these impact on disease management and further impair
functional capacity, health-related quality of life and
prognosis [33,34].
A UK study confirmed that COPD is associated
with numerous co-morbidities; 2,699 patients with
COPD in a UK General Practice research database were
compared with age- and gender-matched controls.
Amongst COPD patients, there was more frequent
angina, cataracts, bone fractures and osteoporosis
[35]. Importantly, these co-morbidities seem to be in-
dependent of smoking and traditional risk factors,
suggesting a ‘COPD specific’ effect [36,37]. In addition
it is thought that other frequently observed co-
morbidities, including musculoskeletal weakness, dia-
betes, and depression, cannot be easily attributed to
smoking [38].
The presence of these co-morbidities has a significant
negative impact. In an analysis of over 20,000 subjects
pooled from the Atherosclerosis Risk in Communities
study and the Cardiovascular Health Study, an increas-
ing number of co-morbidities was associated with a
significantly increased risk of death at all stages of
COPD severity. In addition, risk of hospitalisation within
5 years was increased in the presence of a number of
co-morbidities including diabetes, hypertension and car-
diovascular disease [39,40].
Chronic obstructive pulmonary disease - co-morbid
cognitive dysfunction and dementia
Estimates of cognitive dysfunction in COPD range
from 10 to 61%, depending on the study population
and method of neuropsychological assessment [4,41].
Cognitive impairment appears to be an important de-
terminant of outcomes in COPD, with evidence that
it is associated with poor quality of life, hospitalisa-
tion and reduced survival and is likely to profoundly
influence an individual’s ability to manage their dis-
ease [4,42,43].
A 12 month retrospective database analysis of 126,106
US nursing home residents showed a concurrent diagnosis
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COPD also had short-term memory problems [44]. Mod-
erate to severe cognitive impairment has been shown to
be present in up to 61% of severely hypoxaemic individ-
uals with COPD [41]. The majority of studies show that
patients with COPD have either global impairment or def-
icits in attention, memory and learning and motor func-
tions. In the combined Nocturnal Oxygen Therapy and
the Intermittent Positive Pressure Breathing trials 42% of
patients with COPD had moderate to severe cognitive im-
pairment compared with 21% amongst the control group
[45]. A large longitudinal study showed that self-reported
diagnosis of severe COPD (defined by oxygen use or phys-
ical activity limitation) was associated with a more rapid
decline in a questionnaire marker of cognitive perform-
ance over 6 years [46].
In a well conducted cross-sectional analysis, MCI
was found in 36% of patients with moderate to severe
COPD (versus 12% in controls) [47]. Two longitudinal
studies quantify the risk of developing MCI in pa-
tients with COPD. The first found that a diagnosis of
COPD in mid-life is independently associated with
developing cognitive impairment in later life (hazard
ratio 1.85) [23]. The other found that a diagnosis of COPD
at baseline was associated with an 83% increased risk of
non-amnesic MCI (hazard ratio 1.83 (95% confidence
interval 1.04 to 3.23)) [48]. In addition there was a dose–
response relationship between individuals with COPD
duration of over 5 years at baseline and risk of MCI [48].
By contrast, two studies reported no significant cogni-
tive impairment in COPD. In one, patients with mild
hypoxaemia had worse verbal fluency compared with a
control group, but not outside the normal range [49].
The other compared community-based COPD patients
and a healthy group; no difference in Mini Mental State
Examination (MMSE) was reported, although the COPD
group may have also included cases of asthma - and
MMSE does not measure executive or working memory
functions [50].
In summary, COPD is consistently associated with an
increase in the risk of cognitive impairment, cognitive
decline and dementia. The severity and frequency appear
more marked in those with more advanced disease.
Mechanisms
Early studies of cognitive performance in COPD fo-
cused on hypoxaemia, but cognitive impairment is
present in the absence of hypoxaemia and explains only
a small proportion of the variance in cognitive ability in
those patients with COPD who are hypoxaemic [4,42].
The acute neuropsychological effects of hypoxaemia
have been studied in healthy volunteers; results suggest
that it is responsible for minor deficits in complex rea-
soning, reaction times and word finding, in addition toreduced practice or ‘learning’ effect on repeated testing
[51-53]. Little is known about the chronic effect of hypox-
aemia in the absence of lung pathology. It has been sug-
gested that oxygen-dependent enzymes important in the
synthesis of neurotransmitters such as acetylcholine may
be the pathophysiological pathway responsible for neur-
onal dysfunction during hypoxaemia [54].
Cognitive impairment is a known consequence of
cerebral small-vessel disease and recent neuroimaging
studies suggest that occult cerebrovascular damage
plays a key role in brain damage and dysfunction in
COPD [55,56]. Support for a vascular-mediated brain
pathology is provided by a study in 202 individuals with
dementia collected over 17 years. In this post-mortem
study 45.5% had cerebral atherosclerosis, and in a sub-
group of 52 who went on to have full autopsy, emphy-
sema was present in 36.5% [57].
Arterial stiffness is a non-invasive measure of
vascular function and accurately predicts cardiovascu-
lar and cerebrovascular events. Arterial stiffness is
thought to contribute directly to end-organ vascular
damage through reduced vessel compliance, excessive
pressure pulsatility resulting in vascular remodelling
and impaired blood flow [58-60]. There is evidence of
increased aortic stiffness in COPD, independent of
smoking, which also relates to degree of airflow limita-
tion and percentage emphysema on thoracic computed
tomography scan [60,61]. It has been suggested that
arterial stiffness in COPD may be due to increased
susceptibility to degradation of connective tissue or
accelerated aging. These factors are also implicated in
the development of emphysema, suggesting a potential
shared pathophysiology between pulmonary and vascu-
lar disease in COPD [61].
A comprehensive review of vascular disease in COPD
presents several plausible mechanisms, including systemic
inflammation (interleukin-6, C-reactive protein), oxidative
stress (through activation of matrix metalloproteinases),
physiological stress (hypoxia, sympathetic nervous system
activation), accelerated aging and protease/antiprotease
imbalance. It is argued that many of these pathways
are abnormal in COPD, independently predict cardio-
vascular disease and show direct pathophysiological
links to the development of emphysema [62].
Acute exacerbations of COPD are events characterised
by a change in baseline breathlessness, cough, and or
sputum. Exacerbations are triggered by a combination of
host and external factors, including airway infection and
environmental pollution [63]. COPD exacerbations are
associated with significant risk of death, with an in-
hospital mortality of 7.7% and a 90-day mortality of
13.9% [64]. Cognitive function has been assessed among
patients hospitalised with acute exacerbation and com-
pared with individuals with COPD but without
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over half of those with exacerbation had moderate to se-
vere cognitive impairment, most severely affecting ex-
ecutive function and associated with duration of
hospitalisation and reduced quality of life. In the same
study cognitive impairment did not appear to recover at
3 months. Whilst this could be due to pre-existing cog-
nitive deficit, there are plausible mechanisms by which
exacerbations may influence cognition and brain path-
ology. These relate to the acute physiological changes
associated with infection and respiratory failure. In
addition, recent work suggests that exacerbations are
inflammatory episodes associated with arterial stiffness
and myocardial injury [65].
Brain pathology and lung disease
Smoking has been shown to be associated with a reduc-
tion in volume and density of frontal grey matter, risk of
stroke, pre-clinical brain changes and cerebral atrophy
on magnetic resonance imaging (MRI) [66,67]. Impaired
lung function has been associated with greater cerebral
white matter lesions, independent of conventional vascu-
lar risk factors, including smoking, in large population
studies [68-70]. The Copenhagen Heart study showed a
30% increased risk of cerebral infarction amongst those
with poor lung function (FEV1) [71]. In a smaller com-
munity sample, a significant association was observed
between lung function and both cerebral atrophy and
volume of white matter lesions in men with what was
termed 'chronic respiratory disease', but not in women
or healthy controls [72].
Table 2 summarises studies reporting on the relation-
ship between brain pathology and COPD. Two recent
case–control studies suggest that COPD is associated
with reduced hippocampal and grey matter volumes,
which appear to correlate with measures of disease se-
verity and cognitive function [73,74]. A subgroup of pa-
tients on inhaler medication (that may have included
individuals with COPD) from the Rotterdam population
study had more severe periventricular white matter le-
sions than healthy participants [75]. However, a study on
a smaller but well-defined sample of COPD patients
with and without oxygen dependence found no differ-
ence between patients and healthy controls in either
white matter lesion or cerebral tissue volumes [76].
More recently, a large population study showed that
COPD was an independent risk factor for cerebral
microbleeds at baseline and a significant increased risk
of developing deep and paratentorial cerebral micro-
bleeds over time, suggestive of hypertensive or arteriolo-
sclerotic microangiopathy [55].
Diffusion tensor imaging has been shown to be a more
sensitive measure of white matter microstructural damage
[77]. Recent small, cross-sectional case–control studies inCOPD populations show widespread white matter micro-
structural damage independent of smoking [56,78]. In
healthy older individuals, white matter microstructure in
the corpus collosum correlated with cardiorespiratory fit-
ness (oxygen uptake (VO2) peak r = −0.458) with subse-
quent tractography suggesting pre-frontal connections
associated with motor planning [79].
Resting-state functional MRI measures low-frequency
fluctuations in blood oxygen level-dependent signals in
the brain at rest. In a study comparing stable non-
hypoxaemic individuals with COPD to age-matched con-
trols, patients with COPD had increased activation in
seven out of eight of these networks. This increased acti-
vation of grey matter in COPD may reflect attempts to
overcome damaged white matter pathways [56].
Finally, an MRI spectroscopy study in patients with
non-hypoxic severe COPD showed that cerebral metab-
olism was significantly altered and that the pattern of
derangement differed from that seen in heart failure and
diabetes [80].
There are very few neuroimaging studies specifically in
asthma. An MRI study of 17 people on long-term ste-
roids suggests a possible reduction in hippocampal vol-
ume and declarative memory compared with controls
[18]. In an ovalbumin-induced mouse model of asthma,
there was evidence of impaired learning and hippocam-
pal damage [81]. Finally, a recent MRI study of 19 to
47 year olds with mild to moderate asthma showed that
incidental brain abnormalities were common (62%), of
which 25% were white matter hyperintensities [82].Discussion and conclusions
The benefits of increasing our understanding of the rela-
tionship between chronic lung disease and cognitive im-
pairment are two-fold. First, it may help to identify
modifiable risk factors and therapeutic interventions to
reduce the risk of developing dementia. Second, it pro-
vides the opportunity to reduce the impact of cognitive
impairment on this vulnerable population with a chronic
long-term condition, COPD.
Impaired lung function has been shown to independ-
ently predict cognitive performance but evidence of an
association with cognitive decline is mixed. COPD is a
common multi-system disease with growing evidence of
an accelerated cognitive decline. The mechanisms of
brain pathology and cognitive impairment are likely to
be complex and multi-factorial but MRI suggests a po-
tential COPD-specific cerebrovascular effect. This pro-
vides an appealing therapeutic target for reversing or
halting cognitive decline in this population. Further
studies are therefore required to clarify cerebrovascular
mechanisms of brain pathology and cognitive impair-
ment in COPD.
Table 2 Neuroimaging and chronic obstructive pulmonary disease
Study design Population Cognitive measures Imaging Conclusions/comments Reference
Case control 6 severe COPD NPT MRI SCOPD worse language, executive and visuo-spatial
COPD smoked more and increased previous diabetes.
No difference in brain volumes. SCOPD frontoparietal
and periventricular white matter hyperintensities.
Small differences? smoking related
[85]
13 moderate COPD T1
12 cognitive normal Diffusion
? non-hypoxaemic
Case control 25 stable COPD versus 25 controls NPT MRI COPD worse MMSE, visual reproduction, figure memory
test. COPD reduced GM volume. In COPD some regions
correlated with oxygenation and regional GM volume
was negatively correlated with disease duration. GM
volume in inferior triangular frontal cortex in COPD





N = 165 COPD - MRI susceptibility weighted
imaging
COPD greater CMBs at baseline independent of risk
factors, including medications such as anti-thrombotics.
COPD odds ratio 7.1 of developing deep/paratentorial
CMB
[55]
N = 645 controls
Case control N = 37 mild to moderate COPD MMSE MRI The hippocampal volume was significantly smaller in
COPD. It positively correlated with MMSE score, oxygen
saturation in mild to moderate COPD patients, and
levels of blood oxygen in both mild to moderate and
severe COPD patients
[73]
N = 31 controls
Case control 25 stable non-hypoxaemic NPT MRI volumes, DTI, rfMRI No age-related atrophy, reduced white matter integrity
and increased resting state activation, whiter matter
damage widespread and independent of traditional




Case control N = 25 stable MMSE MRI, DTI Reduced GM density and increased fractional anisotropic
values in COPD. Possible correlations with oxygen levels,
visual tasks and disease duration. But small numbers,
weak correlations
[78]
N = 25 controls
Case control 9 controls NPT MRI volumes COPD had worse global cognition, memory, mood,
but no difference in brain volumes or spectroscopy.
Controlled for age gender and education
[76]




Age 60–90 years - MRI COPD diagnosis had more severe periventricular white
matter lesions. But COPD and oxygen not associated with
subcortical white matter lesions or lacunar infarcts. Low
oxygen saturations independently associated with more
severe periventricular white matter lesions
[75]
Adjusted for age, sex, hypertension,
DM, BMI, pack years, cholesterol, Hb,
MI, LVH.
BMI, body mass index; CMB, cerebral microbleed; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; DTI, diffusion tensor imaging; GM, grey matter; Hb, haemoglobin; LVH, left ventricular
hypertrophy; MI, myocardial infarction; MMSE, mini mental test examination; MRI, magnetic resonance imaging; NPT, neuropsychological test; rfMRI, resting-state functional MRI; SCOPD, severe chronic obstructive














Note: This article is part of a series on The impact of acute and
chronic medical disorders on accelerated cognitive decline, edited
by Carol Brayne and Daniel Davis. Other articles in this series can
be found at http://alzres.com/series/medicaldisorders
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